Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 143,345,904
  • Shares Outstanding, K 575,802
  • Annual Sales, $ 25,424 M
  • Annual Income, $ 7,264 M
  • 60-Month Beta 0.74
  • Price/Sales 5.59
  • Price/Cash Flow 10.73
  • Price/Book 15.27
Trade AMGN with:

Options Overview

Details
  • Implied Volatility 23.46%
  • Historical Volatility 18.50%
  • IV Percentile 6%
  • IV Rank 15.14%
  • IV High 42.23% on 10/28/20
  • IV Low 20.11% on 03/22/21
  • Put/Call Vol Ratio 0.22
  • Today's Volume 1,761
  • Volume Avg (30-Day) 5,760
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 58,403
  • Open Int (30-Day) 64,570

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 4.03
  • Number of Estimates 10
  • High Estimate 4.41
  • Low Estimate 3.76
  • Prior Year 4.17
  • Growth Rate Est. (year over year) -3.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
229.80 +7.81%
on 03/15/21
256.60 -3.45%
on 03/29/21
+17.38 (+7.54%)
since 03/12/21
3-Month
220.25 +12.48%
on 03/04/21
276.69 -10.46%
on 01/28/21
+10.00 (+4.21%)
since 01/13/21
52-Week
210.28 +17.81%
on 10/29/20
276.69 -10.46%
on 01/28/21
+29.47 (+13.50%)
since 04/13/20

Most Recent Stories

More News
Datos Health Announces New Partnership For Study Measuring Impact Of Digital Solutions On Heart Failure Treatment

, /PRNewswire/ -- , a leader in remote care automation, today announced its collaboration with , one of the world's leading independent biotechnology companies, on a new study to evaluate the potential...

AMGN : 247.82 (-0.45%)
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers

Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use...

AMGN : 247.82 (-0.45%)
GH : 154.57 (-0.28%)
AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.

BIIB : 263.50 (+0.27%)
NVS : 86.47 (-1.00%)
AMGN : 247.82 (-0.45%)
ABBV : 107.63 (-0.57%)
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

Style Box ETF report for DEF

DEF : 62.74 (+0.10%)
DGX : 128.79 (-0.05%)
EBAY : 63.53 (+1.42%)
AMGN : 247.82 (-0.45%)
QQQ : 339.61 (+0.87%)
VUG : 274.35 (+0.81%)
Top Research Reports for JPMorgan, Verizon & Chevron

Top Research Reports for JPMorgan, Verizon & Chevron

VZ : 57.51 (-0.05%)
QCOM : 136.83 (-0.44%)
PFE : 37.01 (+0.11%)
JPM : 153.98 (-1.26%)
CVX : 102.03 (+0.25%)
AMGN : 247.82 (-0.45%)
AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

BIIB : 263.50 (+0.27%)
PFE : 37.01 (+0.11%)
AMGN : 247.82 (-0.45%)
ABBV : 107.63 (-0.57%)
Global Biologic Therapeutic Drugs Market (2021 to 2025) - Featuring Amgen, Baxter and China Biologic Products Among Others

The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

AMGN : 247.82 (-0.45%)
CBPO : 118.45 (-0.06%)
Global Uveitis Drugs Market- AbbVie Inc., Alimera Sciences Inc., Amgen Inc., among others to contribute to the market growth|Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2025

, /PRNewswire/ --

ABBV : 107.63 (-0.57%)
ALIM : 9.75 (+5.18%)
AMGN : 247.82 (-0.45%)
4 Biotech Stocks to Buy for the Q2 2021

The biotechnology industry is expected to expand significantly over the next few years on the back of favorable government initiatives and the emergence of innovative players. Amgen (AMGN), Gilead Sciences...

AMGN : 247.82 (-0.45%)
GILD : 64.46 (-0.31%)
QGEN : 51.76 (+0.35%)
JAZZ : 161.05 (-0.76%)
Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

SNY : 50.21 (-0.08%)
BMY : 63.31 (+0.99%)
AMGN : 247.82 (-0.45%)
TBIO : 17.08 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

3rd Resistance Point 252.24
2nd Resistance Point 251.12
1st Resistance Point 250.03
Last Price 247.82
1st Support Level 247.82
2nd Support Level 246.70
3rd Support Level 245.61

See More

52-Week High 276.69
Fibonacci 61.8% 251.32
Last Price 247.82
Fibonacci 50% 243.49
Fibonacci 38.2% 235.65
52-Week Low 210.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar